We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-13.22%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.03B
AUM Growth
+$135M
Cap. Flow
+$465M
Cap. Flow %
22.9%
Top 10 Hldgs %
63.8%
Holding
57
New
6
Increased
19
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$187M
2
STE icon
Steris
STE
+$105M
3
CORT icon
Corcept Therapeutics
CORT
+$55M
4
CTLT
CATALENT, INC.
CTLT
+$36.8M
5
CABO icon
Cable One
CABO
+$36.4M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$29.9M
2
AAPL icon
Apple
AAPL
+$22.6M
3
INGN icon
Inogen
INGN
+$16.2M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$13.9M
5
NKTX icon
Nkarta
NKTX
+$8.06M

Sector Composition

Rank Sector Weight
1 Healthcare 58.54%
2 Technology 15.07%
3 Financials 6.4%
4 Communication Services 2.82%
5 Consumer Discretionary 2.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRTX
51
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$3.2M 0.16%
2,459,021
– –
VRNA
52
DELISTED
Verona Pharma
VRNA
$3.19M 0.16%
761,205
– –
ALGS icon
53
Aligos Therapeutics
ALGS
$34.9M
$2.36M 0.12%
78,000
– –
SPRO icon
54
Spero Therapeutics
SPRO
$73M
$347K 0.02%
468,902
– –
IOVA icon
55
Iovance Biotherapeutics
IOVA
$2.87B
– –
-836,518
Closed -$13.9M
PRAX icon
56
Praxis Precision Medicines
PRAX
$10.1B
– –
-16,667
Closed -$2.55M
CMPI
57
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
– –
-2,161,990
Closed -$6.9M
1 2
3

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q2 2022 Portfolio in Review

As of Q2 2022, Novo Holdings A/S held 57 positions worth $2.03B, up 7.1% from $1.9B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Novo Holdings A/S deployed $465M of net new capital in Q2 2022, opening 6 new positions and adding to 19 existing holdings. Its largest new stake was Stryker: 796,941 shares worth $159M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 49% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $29.9M trimmed.

  • Novo Holdings A/S's largest Q2 2022 buy was Stryker: 796,941 shares worth $159M.
  • Novo Holdings A/S added most to CATALENT, INC. in Q2 2022, an estimated $36.8M increase.
  • Novo Holdings A/S's biggest Q2 2022 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $29.9M.
  • Novo Holdings A/S fully exited Iovance Biotherapeutics in Q2 2022, selling an estimated $13.9M.
  • Novo Holdings A/S's ten largest holdings make up 64% of its $2.03B portfolio in Q2 2022.
  • Novo Holdings A/S opened 6 new positions and closed 3 in Q2 2022.
  • Novo Holdings A/S's portfolio value rose 7.1% quarter-over-quarter to $2.03B.

Based on Novo Holdings A/S's 13F filing for Q2 2022, filed 15 Aug 2022.